...
首页> 外文期刊>Molecular & cellular proteomics: MCP >PTMScan direct: Identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS
【24h】

PTMScan direct: Identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS

机译:PTMScan direct:通过免疫亲和富集与LC-MS / MS结合,从关键信号蛋白中鉴定和定量肽

获取原文
获取原文并翻译 | 示例

摘要

Proteomic studies of post-translational modifications by metal affinity or antibody-based methods often employ data-dependent analysis, providing rich data sets that consist of randomly sampled identified peptides because of the dynamic response of the mass spectrometer. This can complicate the primary goal of programs for drug development, mutational analysis, and kinase profiling studies, which is to monitor how multiple nodes of known, critical signaling pathways are affected by a variety of treatment conditions. Cell Signaling Technology has developed an immunoaffinity-based LC-MS/MS method called PTMScan Direct for multiplexed analysis of these important signaling proteins. PTMScan Direct enables the identification and quantification of hundreds of peptides derived from specific proteins in signaling pathways or specific protein types. Cell lines, tissues, or xenografts can be used as starting material. PTMScan Direct is compatible with both SILAC and label-free quantification. Current PTMScan Direct reagents target key nodes of many signaling pathways (PTMScan Direct: Multipathway), serine/threonine kinases, tyrosine kinases, and the Akt/PI3K pathway. Validation of each reagent includes score filtering of MS/MS assignments, filtering by identification of peptides derived from expected targets, identification of peptides homologous to expected targets, minimum signal intensity of peptide ions, and dependence upon the presence of the reagent itself compared with a negative control. The Multipathway reagent was used to study sensitivity of human cancer cell lines to receptor tyrosine kinase inhibitors and showed consistent results with previously published studies. The Ser/Thr kinase reagent was used to compare relative levels of kinase-derived phosphopeptides in mouse liver, brain, and embryo, showing tissuespecific activity of many kinases including Akt and PKC family members. PTMScan Direct will be a powerful quantitative method for elucidation of changes in signaling in a wide array of experimental systems, combining the specificity of traditional biochemical methods with the high number of data points and dynamic range of proteomic methods.
机译:通过金属亲和力或基于抗体的方法对翻译后修饰进行的蛋白质组学研究通常采用依赖数据的分析,由于质谱仪的动态响应,该数据集提供了丰富的数据集,这些数据集由随机采样的鉴定出的肽组成。这会使药物开发,突变分析和激酶谱研究的计划的主要目标变得复杂,该程序的目的是监视已知关键信号通路的多个节点如何受到多种治疗条件的影响。细胞信号技术已开发出一种基于免疫亲和力的LC-MS / MS方法,称为PTMScan Direct,可以对这些重要的信号蛋白进行多重分析。 PTMScan Direct可以识别和定量从信号途径或特定蛋白质类型中的特定蛋白质衍生的数百种肽。细胞系,组织或异种移植物可用作起始材料。 PTMScan Direct与SILAC和无标签定量均兼容。当前的PTMScan Direct试剂靶向许多信号通路(PTMScan Direct:多通路),丝氨酸/苏氨酸激酶,酪氨酸激酶和Akt / PI3K通路的关键节​​点。每种试剂的验证包括:对MS / MS分配进行评分过滤,通过鉴定源自预期靶标的肽段,进行与预期靶标同源的肽段的鉴定,肽离子的最小信号强度以及与试剂本身相比的依赖性来进行过滤。阴性对照。 Multipathway试剂用于研究人癌细胞对受体酪氨酸激酶抑制剂的敏感性,并显示与先前发表的研究一致的结果。 Ser / Thr激酶试剂用于比较小鼠肝脏,大脑和胚胎中激酶衍生的磷酸肽的相对水平,显示出包括Akt和PKC家族在内的许多激酶的组织特异性活性。 PTMScan Direct将是一种强大的定量方法,用于阐明各种实验系统中信号的变化,将传统生化方法的特异性与大量数据点和蛋白质组学方法的动态范围相结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号